TherapeuticsMD (TXMD) investor relations material

Executive summary

• Transitioned to a pharmaceutical royalty company in December 2022, licensing products and receiving royalties instead of direct commercial operations.

• Main revenue sources are royalties from Mayne Pharma, Theramex, and Knight for licensed products in the U.S. and internationally.

• Reported net income from continuing operations of $103K for Q1 2026, reversing a net loss of $636K in Q1 2025.

• Operating expenses decreased by 13.6% to $1,447K, driven by lower professional fees, share-based compensation, and absence of prior write-off expenses.

• All former commercial operations are now classified as discontinued operations.

Financial highlights

• License revenue for Q1 2026 was $724K, up from $393K in Q1 2025, mainly from the Mayne License Agreement.

• Net income for Q1 2026 was $103K, compared to a net loss of $636K in Q1 2025.

• Cash and cash equivalents as of March 31, 2026, totaled $8.4M.

• Net cash provided by operating activities was $944K in Q1 2026, up from $699K in Q1 2025.

• Operating expenses reduced by 13.6% compared to the same quarter last year.

Outlook and guidance

• Substantial doubt exists about the ability to continue as a going concern for the next twelve months due to uncertainties in royalty growth, litigation outcomes, and capital market conditions.

• May need to raise additional capital through equity or debt financing to fund operations.

• Actively evaluating strategic alternatives, including potential acquisition, merger, asset sale, or other business combinations, with no set timetable or assurance of outcome.